BEEFING UP SKINNY LABELS: INDUCED INFRINGEMENT AS A QUESTION OF LAW
The cost of pharmaceuticals has a massive influence on the healthcare system. The global pharmaceutical industry had a revenue of $1.27 trillion in 2020, with revenue of sales in North America accounting for approximately half of that. This colossal market is seen as a burden to many, and a majority...
Gespeichert in:
| Veröffentlicht in: | The Notre Dame law review 2022-04, Vol.97 (4), p.1707 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 1707 |
| container_title | The Notre Dame law review |
| container_volume | 97 |
| creator | Potter, Garretl T |
| description | The cost of pharmaceuticals has a massive influence on the healthcare system. The global pharmaceutical industry had a revenue of $1.27 trillion in 2020, with revenue of sales in North America accounting for approximately half of that. This colossal market is seen as a burden to many, and a majority of United States citizens shows unified support for decreasing the price of drugs. Government officials from both Democratic and Republican parties have floated plans to decrease the cost of healthcare by incorporating more use of generic drugs which would serve as competition to brand drug manufacturers that otherwise retain a monopoly on the drug market. One way that generic drug manufacturers are able to compete with brand manufacturers is through the use of "skinny labels." Under the Hatch-Waxman Act of 1984, drug manufacturers can introduce a generic version of a pioneer drug to the market so long as any patented methods of use or treatment are "carved out" of the drug label, making it a so-called "skinny label. |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2685095810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A708531077</galeid><sourcerecordid>A708531077</sourcerecordid><originalsourceid>FETCH-LOGICAL-g325t-7f50a04b904d5286c37077bc8762cffad0ca4ab1b1ffeea1ad9d8066e68ce3833</originalsourceid><addsrcrecordid>eNptzd9PgzAQB3AeNHFO_4cmvoppgf6Yb4yVSUSmMmJ8IqW0yLKBUvj_baKJM1kuuW9y-dzdmTODNMCujxG-cC6N2UEIiYeCmRMtOY-TbA2KZ5A_Jln2DtJwydP8HiTZqoj4ymb8agV_4tkWhDkIwUvB822yycAmtvrtyjnXYm_U9W_OnSLm2-jBTTfrJApTt_E9PLpUYyhgUC1gUGOPEelTSGklGSWe1FrUUIpAVKhCWislkKgXNYOEKMKk8pnvz52bn7ufQ_81KTOWu34aOvuy9AjDcIEZgn-qEXtVtp3ux0HIQ2tkGVLIsI_sV6vcE6pRnRrEvu-Ubu34n7874W3V6tDKkwu3RwvVZNpOGdtM23yMphGTMcf8G44OeQ8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685095810</pqid></control><display><type>article</type><title>BEEFING UP SKINNY LABELS: INDUCED INFRINGEMENT AS A QUESTION OF LAW</title><source>EZB-FREE-00999 freely available EZB journals</source><source>HeinOnline Law Journal Library</source><creator>Potter, Garretl T</creator><creatorcontrib>Potter, Garretl T</creatorcontrib><description>The cost of pharmaceuticals has a massive influence on the healthcare system. The global pharmaceutical industry had a revenue of $1.27 trillion in 2020, with revenue of sales in North America accounting for approximately half of that. This colossal market is seen as a burden to many, and a majority of United States citizens shows unified support for decreasing the price of drugs. Government officials from both Democratic and Republican parties have floated plans to decrease the cost of healthcare by incorporating more use of generic drugs which would serve as competition to brand drug manufacturers that otherwise retain a monopoly on the drug market. One way that generic drug manufacturers are able to compete with brand manufacturers is through the use of "skinny labels." Under the Hatch-Waxman Act of 1984, drug manufacturers can introduce a generic version of a pioneer drug to the market so long as any patented methods of use or treatment are "carved out" of the drug label, making it a so-called "skinny label.</description><identifier>ISSN: 0745-3515</identifier><language>eng</language><publisher>Notre Dame: University of Notre Dame Law School</publisher><subject>Analysis ; Bench trials ; Composition ; Copyright infringement ; Drug delivery systems ; Equity (Law) ; Evaluation ; Generic drugs ; Intent (Law) ; Labeling ; Law and fact ; Laws, regulations and rules ; Management ; Manufacturers ; Patent infringement ; Patient package inserts ; Pharmaceutical industry ; Product development ; Proprietary drugs ; Revenue ; Right to trial by jury</subject><ispartof>The Notre Dame law review, 2022-04, Vol.97 (4), p.1707</ispartof><rights>COPYRIGHT 2022 University of Notre Dame Law School</rights><rights>Copyright Notre Dame Law Review 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Potter, Garretl T</creatorcontrib><title>BEEFING UP SKINNY LABELS: INDUCED INFRINGEMENT AS A QUESTION OF LAW</title><title>The Notre Dame law review</title><description>The cost of pharmaceuticals has a massive influence on the healthcare system. The global pharmaceutical industry had a revenue of $1.27 trillion in 2020, with revenue of sales in North America accounting for approximately half of that. This colossal market is seen as a burden to many, and a majority of United States citizens shows unified support for decreasing the price of drugs. Government officials from both Democratic and Republican parties have floated plans to decrease the cost of healthcare by incorporating more use of generic drugs which would serve as competition to brand drug manufacturers that otherwise retain a monopoly on the drug market. One way that generic drug manufacturers are able to compete with brand manufacturers is through the use of "skinny labels." Under the Hatch-Waxman Act of 1984, drug manufacturers can introduce a generic version of a pioneer drug to the market so long as any patented methods of use or treatment are "carved out" of the drug label, making it a so-called "skinny label.</description><subject>Analysis</subject><subject>Bench trials</subject><subject>Composition</subject><subject>Copyright infringement</subject><subject>Drug delivery systems</subject><subject>Equity (Law)</subject><subject>Evaluation</subject><subject>Generic drugs</subject><subject>Intent (Law)</subject><subject>Labeling</subject><subject>Law and fact</subject><subject>Laws, regulations and rules</subject><subject>Management</subject><subject>Manufacturers</subject><subject>Patent infringement</subject><subject>Patient package inserts</subject><subject>Pharmaceutical industry</subject><subject>Product development</subject><subject>Proprietary drugs</subject><subject>Revenue</subject><subject>Right to trial by jury</subject><issn>0745-3515</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>N95</sourceid><recordid>eNptzd9PgzAQB3AeNHFO_4cmvoppgf6Yb4yVSUSmMmJ8IqW0yLKBUvj_baKJM1kuuW9y-dzdmTODNMCujxG-cC6N2UEIiYeCmRMtOY-TbA2KZ5A_Jln2DtJwydP8HiTZqoj4ymb8agV_4tkWhDkIwUvB822yycAmtvrtyjnXYm_U9W_OnSLm2-jBTTfrJApTt_E9PLpUYyhgUC1gUGOPEelTSGklGSWe1FrUUIpAVKhCWislkKgXNYOEKMKk8pnvz52bn7ufQ_81KTOWu34aOvuy9AjDcIEZgn-qEXtVtp3ux0HIQ2tkGVLIsI_sV6vcE6pRnRrEvu-Ubu34n7874W3V6tDKkwu3RwvVZNpOGdtM23yMphGTMcf8G44OeQ8</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Potter, Garretl T</creator><general>University of Notre Dame Law School</general><general>Notre Dame Law Review</general><scope>N95</scope><scope>XI7</scope><scope>ILT</scope><scope>K7.</scope></search><sort><creationdate>20220401</creationdate><title>BEEFING UP SKINNY LABELS: INDUCED INFRINGEMENT AS A QUESTION OF LAW</title><author>Potter, Garretl T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g325t-7f50a04b904d5286c37077bc8762cffad0ca4ab1b1ffeea1ad9d8066e68ce3833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Bench trials</topic><topic>Composition</topic><topic>Copyright infringement</topic><topic>Drug delivery systems</topic><topic>Equity (Law)</topic><topic>Evaluation</topic><topic>Generic drugs</topic><topic>Intent (Law)</topic><topic>Labeling</topic><topic>Law and fact</topic><topic>Laws, regulations and rules</topic><topic>Management</topic><topic>Manufacturers</topic><topic>Patent infringement</topic><topic>Patient package inserts</topic><topic>Pharmaceutical industry</topic><topic>Product development</topic><topic>Proprietary drugs</topic><topic>Revenue</topic><topic>Right to trial by jury</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Potter, Garretl T</creatorcontrib><collection>Gale Business: Insights</collection><collection>Business Insights: Essentials</collection><collection>Gale OneFile: LegalTrac</collection><collection>ProQuest Criminal Justice (Alumni)</collection><jtitle>The Notre Dame law review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Potter, Garretl T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BEEFING UP SKINNY LABELS: INDUCED INFRINGEMENT AS A QUESTION OF LAW</atitle><jtitle>The Notre Dame law review</jtitle><date>2022-04-01</date><risdate>2022</risdate><volume>97</volume><issue>4</issue><spage>1707</spage><pages>1707-</pages><issn>0745-3515</issn><abstract>The cost of pharmaceuticals has a massive influence on the healthcare system. The global pharmaceutical industry had a revenue of $1.27 trillion in 2020, with revenue of sales in North America accounting for approximately half of that. This colossal market is seen as a burden to many, and a majority of United States citizens shows unified support for decreasing the price of drugs. Government officials from both Democratic and Republican parties have floated plans to decrease the cost of healthcare by incorporating more use of generic drugs which would serve as competition to brand drug manufacturers that otherwise retain a monopoly on the drug market. One way that generic drug manufacturers are able to compete with brand manufacturers is through the use of "skinny labels." Under the Hatch-Waxman Act of 1984, drug manufacturers can introduce a generic version of a pioneer drug to the market so long as any patented methods of use or treatment are "carved out" of the drug label, making it a so-called "skinny label.</abstract><cop>Notre Dame</cop><pub>University of Notre Dame Law School</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0745-3515 |
| ispartof | The Notre Dame law review, 2022-04, Vol.97 (4), p.1707 |
| issn | 0745-3515 |
| language | eng |
| recordid | cdi_proquest_journals_2685095810 |
| source | EZB-FREE-00999 freely available EZB journals; HeinOnline Law Journal Library |
| subjects | Analysis Bench trials Composition Copyright infringement Drug delivery systems Equity (Law) Evaluation Generic drugs Intent (Law) Labeling Law and fact Laws, regulations and rules Management Manufacturers Patent infringement Patient package inserts Pharmaceutical industry Product development Proprietary drugs Revenue Right to trial by jury |
| title | BEEFING UP SKINNY LABELS: INDUCED INFRINGEMENT AS A QUESTION OF LAW |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A59%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BEEFING%20UP%20SKINNY%20LABELS:%20INDUCED%20INFRINGEMENT%20AS%20A%20QUESTION%20OF%20LAW&rft.jtitle=The%20Notre%20Dame%20law%20review&rft.au=Potter,%20Garretl%20T&rft.date=2022-04-01&rft.volume=97&rft.issue=4&rft.spage=1707&rft.pages=1707-&rft.issn=0745-3515&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA708531077%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2685095810&rft_id=info:pmid/&rft_galeid=A708531077&rfr_iscdi=true |